S&P 500 ekes out gain while banks drag on Dow
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Allergen (AGN) PT Raised to $280 at Leerink Partners Following 4Q
February 9, 2017 8:07 AM ESTLeerink Partners raised its price target on Allergen (NYSE: AGN) to $280.00 (from $271.00) while maintaining a Outperform rating.
Analyst Jason Gerberry commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic... More
Gild Sciences (GILD) PT Drops to $75 at BMO on Bad Guidance
February 9, 2017 6:41 AM ESTBMO Capital Markets analyst M. Ian Somaiya maintains Market Perform rating, but drops price target on Gild Sciences (NASDAQ: GILD) to $75 (from $88), as the company delivered guidance well below consensus, forcing the Street to cut estimates.
Somaiya comments, "We are maintaining our Market... More
Gilead Sciences (GILD): 'Acquisition Wanted! - Please Apply Within'
February 8, 2017 11:09 AM ESTFollowing its 'kitchen sink' HCV guidance and subsequent 9% sell-off, the urgency for Gilead Sciences (NASDAQ: GILD) to make an acquisition continues to intensify. On the call, the company essentially admitted that it cannot grow over the next few years without a... More
